Oncolytic Viruses

Oncolytic viruses (OVs) are powerful novel therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining FDA approval, interest in OVs has been enhanced greatly. However, in spite of extensive research, oncolytic virotherapy has shown limited efficiency  against solid tumors. Recent advancements in viral delivery platforms, viral retargeting, genetic editing, OV-based gene therapy, tracking strategies and combination strategies have the capability to widen the applications of oncolytic virotherapy in oncology. Directed evolution was applied on human adenovirus, which is one of many viruses that are being established or developed as oncolytic agents, to create a highly selective and yet potent oncolytic vaccine. As a result of this process, a novel chimeric member of the group B adenoviruses named ColoAd1 was produced. This hybrid of adenovirus serotypes Ad3 and Ad11p shows much higher effectiveness and tumour selectivity than the control viruses.  

High Impact List of Articles

Relevant Topics in